HC Wainwright & Co. Reiterates Buy on Climb Bio, Maintains $20 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 88.5%

Neg 0% Neu 88.5% Pos 0%

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Climb Bio (NASDAQ:CLYM) with a Buy and maintains $20 price target.